Zions Bancorporation N.A. Purchases 11,995 Shares of Certara, Inc. (NASDAQ:CERT)

Zions Bancorporation N.A. grew its holdings in shares of Certara, Inc. (NASDAQ:CERT) by 18.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 76,811 shares of the company’s stock after buying an additional 11,995 shares during the period. Zions Bancorporation N.A.’s holdings in Certara were worth $899,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CERT. Daventry Group LP increased its stake in shares of Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after acquiring an additional 791,405 shares in the last quarter. Kopion Asset Management LLC bought a new position in shares of Certara in the 3rd quarter worth about $4,457,000. Sei Investments Co. increased its stake in shares of Certara by 39.5% in the 2nd quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock worth $13,821,000 after acquiring an additional 282,357 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Certara by 9.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after acquiring an additional 273,095 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Certara by 9.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,773,892 shares of the company’s stock worth $38,418,000 after acquiring an additional 248,448 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Stock Performance

Shares of CERT stock opened at $10.53 on Friday. The company has a 50 day moving average price of $10.93 and a 200-day moving average price of $13.54. Certara, Inc. has a 52 week low of $9.99 and a 52 week high of $19.87. The firm has a market capitalization of $1.70 billion, a PE ratio of -52.65, a P/E/G ratio of 5.52 and a beta of 1.51. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. During the same period in the previous year, the business posted $0.06 earnings per share. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, equities research analysts expect that Certara, Inc. will post 0.27 earnings per share for the current year.

Analyst Ratings Changes

CERT has been the subject of several research reports. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Friday, September 27th. Barclays reduced their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Finally, Robert W. Baird reduced their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Six analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.92.

Insider Transactions at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This trade represents a 9.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. The trade was a 33.94 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.39% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.